Rafaela Ferrer de Oliveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rafaela Ferrer de Oliveira has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Ivana Márcia Alves Diniz
Department of Restorative Dentistry, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
3 shared publications - Luiza de Almeida Queiroz Ferreira
Universidade Federal de Minas Gerais
3 shared publications - Ricardo Alves Mesquita
Department of Oral Surgery, Pathology and Clinical Dentistry School of Dentistry, Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil
3 shared publications - Tarcília Aparecida Silva
Department of Oral Surgery, Pathology and Clinical Dentistry, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
3 shared publications - Márcia Martins Marques
Department of Stomatology, School of Dentistry, University of São Paulo, São Paulo, Brazil
2 shared publications - Alexander Birbrair
University of Wisconsin-Madison
1 shared publication
Latest Publications
- Open Access
- 18 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (18) , 6079-6089
Plasmin-mediated fibrinolysis is required for hematopoietic recovery after 5-FU-induced myeloablation
Hematopoietic recovery following myeloablation plays a critical role in the survival of the patients that receive chemotherapy or hematopoietic stem cell transplantation. Understanding the mechanisms underlying hematopoiesis helps identify molecular and/or cellular determinants that could be targeted to enhance hematopoietic recovery. Although several mechanisms by which the plasminogen activation system promotes hematopoietic recovery after myelosuppression have been reported, the specific role fibrinolysis plays in hematopoietic recovery is unclear. The current study employs 5-Fluorouracil-mediated myeloablation in murine models and provides a clear demonstration of uniform extravascular fibrin deposits in the bone marrow niche upon myeloablation. Persistent fibrin deposits in plasminogen-deficient mice lead to failure of hematopoietic recovery. Genetic and pharmacological depletion of fibrinogen following myeloablation restored hematopoietic recovery, revealing the critical role of fibrin in this process. Moreover, defective fibrinolysis led to delayed hematopoietic recovery via a mechanism that involves fibrin engagement with the major myeloid integrin aMb2. Importantly, similar fibrin-rich marrow niches were also observed in human bone marrow injury and failure states. The study identifies a novel molecular pathway that could be therapeutically targeted to enhance hematopoietic recovery following myeloablation.
- 18 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (18) , 6079-6089
Open AccessPlasmin-mediated fibrinolysis is required for hematopoietic recovery after 5-FU-induced myeloablation
Hematopoietic recovery following myeloablation plays a critical role in the survival of the patients that receive chemotherapy or hematopoietic stem cell transplantation. Understanding the mechanisms underlying hematopoiesis helps identify molecular and/or cellular determinants that could be targeted to enhance hematopoietic recovery. Although several mechanisms by which the plasminogen activation system promotes hematopoietic recovery after myelosuppression have been reported, the specific role fibrinolysis plays in hematopoietic recovery is unclear. The current study employs 5-Fluorouracil-mediated myeloablation in murine models and provides a clear demonstration of uniform extravascular fibrin deposits in the bone marrow niche upon myeloablation. Persistent fibrin deposits in plasminogen-deficient mice lead to failure of hematopoietic recovery. Genetic and pharmacological depletion of fibrinogen following myeloablation restored hematopoietic recovery, revealing the critical role of fibrin in this process. Moreover, defective fibrinolysis led to delayed hematopoietic recovery via a mechanism that involves fibrin engagement with the major myeloid integrin aMb2. Importantly, similar fibrin-rich marrow niches were also observed in human bone marrow injury and failure states. The study identifies a novel molecular pathway that could be therapeutically targeted to enhance hematopoietic recovery following myeloablation.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Archives of Biology and Technology
- Vol. 67, e24230003
Biogran Grafting in Rat Tibia Defects - A Model of High Bone Metabolism Site
We investigated the Biogran on bone repair and metabolism at several time-intervals upon grafting into rat tibia artificial defects. The biomaterial was thoroughly characterized in vitro, and its dissolution behavior upon immersion was assessed in simulated body fluid (SBF) solution for 1, 3, 7, 14, and 30 days. Biogran was also assessed by in vitro hydroxyapatite formation in SBF solution, which is a marker for bioactive behavior. In vivo, distal and proximal bone defects were performed in the Wistar rat's right tibia and filled according to the experimental groups: I) negative control, no filling; II) positive control, 10 mg of autogenous bone; and III) 10 mg of Biogran. Animals were euthanized at 1, 2, 3, 4, 7, and 10 weeks. Bone neoformation was analyzed using histomorphometry (proximal defect), and local levels of bone morphogenetic protein 2 (BMP-2) were measured using the ELISA assay (distal defect). In vitro, the Biogran sample showed a fast dissolution rate within the first 7 days, parallel to the formation of the hydroxyapatite layer. In vivo, the sample was progressively resorbed at a higher rate within the first month until it became almost absent at week 10th. The sample presented similar or higher bone neoformation concerning the autogenous bone. BMP-2 levels were sustained in the Biogran group (around 200 pg/mg) and detected until the last experimental time with a significant difference compared with the controls. Results suggest Biogran is a candidate for hard tissue engineering even in highly active bone remodeling sites.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Archives of Biology and Technology
- Vol. 67, e24230003
Open AccessBiogran Grafting in Rat Tibia Defects - A Model of High Bone Metabolism Site
We investigated the Biogran on bone repair and metabolism at several time-intervals upon grafting into rat tibia artificial defects. The biomaterial was thoroughly characterized in vitro, and its dissolution behavior upon immersion was assessed in simulated body fluid (SBF) solution for 1, 3, 7, 14, and 30 days. Biogran was also assessed by in vitro hydroxyapatite formation in SBF solution, which is a marker for bioactive behavior. In vivo, distal and proximal bone defects were performed in the Wistar rat's right tibia and filled according to the experimental groups: I) negative control, no filling; II) positive control, 10 mg of autogenous bone; and III) 10 mg of Biogran. Animals were euthanized at 1, 2, 3, 4, 7, and 10 weeks. Bone neoformation was analyzed using histomorphometry (proximal defect), and local levels of bone morphogenetic protein 2 (BMP-2) were measured using the ELISA assay (distal defect). In vitro, the Biogran sample showed a fast dissolution rate within the first 7 days, parallel to the formation of the hydroxyapatite layer. In vivo, the sample was progressively resorbed at a higher rate within the first month until it became almost absent at week 10th. The sample presented similar or higher bone neoformation concerning the autogenous bone. BMP-2 levels were sustained in the Biogran group (around 200 pg/mg) and detected until the last experimental time with a significant difference compared with the controls. Results suggest Biogran is a candidate for hard tissue engineering even in highly active bone remodeling sites.
- 27 April 2022
- Published by Wiley in Journal of Cellular Physiology
- Vol. 237 (4)
Cover Image, Volume 237, Number 4, April 2022
- 27 April 2022
- Published by Wiley in Journal of Cellular Physiology
- Vol. 237 (4)
Cover Image, Volume 237, Number 4, April 2022
- 15 April 2022
- Published by Wiley in Wound Repair and Regeneration
- Vol. 30 (3) , 345-356
Interplay between epithelial and mesenchymal cells unveils essential proinflammatory and pro‐resolutive mediators modulated by photobiomodulation therapy at 660 nm
Photobiomodulation therapy (PBMT) has been widely used to promote tissue repair. However, PBMT's critical roles in the epithelial and mesenchymal tissues interactions are still barely known. Herein, we investigated light parameters on challenged keratinocytes (KC)—i.e., cultivated under oxidative stress—solely or associated with fibroblasts (FB) in a co‐culture system. Cells were treated with PBMT at the wavelength of 660 nm, at 20 mW and 0.71 W/cm2. Three different energy densities were primarily evaluated on KC: 1 (1.4 s), 5 (7 s), and 50 J/cm2 (70 s). Next, KC and FB were co‐cultured and assessed at 5 J/cm2. This energy density was also tested in ex vivo murine skin samples. Our main data suggest that PBMT can increase cellular proliferation at low doses and cell migration in a biphasic mode (1 and 50 J/cm2), both further confirmed by the epidermal growth factor receptor ligand—amphiregulin—upregulation. IL‐1RA mRNA—the IL‐1β (interleukin‐1β) receptor antagonist recognized to fasten wound repair—was upregulated in the co‐culture system. Upon PBMT, the ex vivo findings showed a progressive increase in the epidermal thickness, although presenting qualitatively less differentiated epithelium than the control group. In conclusion, PBMT effects are dependent on the cellular interactions with the surrounding microenvironment. Ultimately, PBMT is anti‐inflammatory and contributes to the expression of critical mediators of wound repair.
- 15 April 2022
- Published by Wiley in Wound Repair and Regeneration
- Vol. 30 (3) , 345-356
Interplay between epithelial and mesenchymal cells unveils essential proinflammatory and pro‐resolutive mediators modulated by photobiomodulation therapy at 660 nm
Photobiomodulation therapy (PBMT) has been widely used to promote tissue repair. However, PBMT's critical roles in the epithelial and mesenchymal tissues interactions are still barely known. Herein, we investigated light parameters on challenged keratinocytes (KC)—i.e., cultivated under oxidative stress—solely or associated with fibroblasts (FB) in a co‐culture system. Cells were treated with PBMT at the wavelength of 660 nm, at 20 mW and 0.71 W/cm2. Three different energy densities were primarily evaluated on KC: 1 (1.4 s), 5 (7 s), and 50 J/cm2 (70 s). Next, KC and FB were co‐cultured and assessed at 5 J/cm2. This energy density was also tested in ex vivo murine skin samples. Our main data suggest that PBMT can increase cellular proliferation at low doses and cell migration in a biphasic mode (1 and 50 J/cm2), both further confirmed by the epidermal growth factor receptor ligand—amphiregulin—upregulation. IL‐1RA mRNA—the IL‐1β (interleukin‐1β) receptor antagonist recognized to fasten wound repair—was upregulated in the co‐culture system. Upon PBMT, the ex vivo findings showed a progressive increase in the epidermal thickness, although presenting qualitatively less differentiated epithelium than the control group. In conclusion, PBMT effects are dependent on the cellular interactions with the surrounding microenvironment. Ultimately, PBMT is anti‐inflammatory and contributes to the expression of critical mediators of wound repair.